| Quote | Spy ELN NEW ![]() |
Message Board | |||||
|
Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders. |
|
Top 10 Analyst Upgrades, Downgrades, Initiations
FITB GCI GT HAL ELN PVTB URBN MT BMRN FSLR Linked by 24/7 Wall St. - October 29, 07:45AM from (247wallst.com) These are this Thursday morning's top 10 analyst upgrades, downgrades, and initiations we have seen in early research calls from Wall Street: more ...
Targeting Tysabri
ABT JNJ ELN BIIB Linked by Forbes - October 27, 04:14PM from (www.forbes.com) The drug's inventor believes a new test might identify people who are less at risk for a deadly side effect. more ...
Elan Corporation Posts Q3 Profit of $0.11
ELN Linked by StreetInsider - October 21, 07:01AM from (www.streetinsider.com) more ...
Elan Announces Webcast of Third Quarter 2009 Financial Results
ELN Linked by BusinessWire - October 07, 04:30PM from (www.businesswire.com) Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, October 21, 2009 at 8:30 more ...
Elan Cures Breach of Tysabri(R) Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson
ELN Linked by BusinessWire - September 14, 04:30PM from (www.businesswire.com) Elan Corporation, plc (NYSE: ELN) today announced that it has cured an unintended breach of its Tysabri Collaboration Agreement more ...
Partners Behind an M.S. Drug Take Their Dispute to Court
ELN BIIB Linked by NYTimes - August 06, 06:56PM from (feeds.nytimes.com) Biogen says its partner, Elan, has violated their deal to share ownership of the drug Tysabri. Elan says it has not. more ...
Finding biotech's big winners
JNJ ELN BIIB MNKD ARRY Linked by BloggingStocks - July 22, 11:43AM from (www.pheedcontent.com) During 2009, drug treatments for ten diseases in the U.S. will bring pharma companies nearly $170 billion in sales. Those more ...
The Next Blockbuster Drugs: A $170 Billion Opportunity
ABT WYE BMY LLY MRK PFE JNJ AMGN NVO ELN TEVA BIIB GILD MNKD AZN THRX ARRY NVS SNY GSK Linked by 24/7 Wall St. - July 22, 05:01AM from (feedproxy.google.com) Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line more ...
Elan Corp Tops Q2 View By 2c
ELN Linked by StreetInsider - July 21, 07:28AM from (www.streetinsider.com) more ...
Elan upgraded to "buy"
ELN Linked by newratings - July 20, 02:43PM from (www.newratings.com) NEW YORK, July 20 (newratings.com) - Analysts at UBS upgrade Elan (ticker: ELN) from "neutral" to "buy." more ...
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2009 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF. |
|